BridgeBio Pharma (Nasdaq: BBIO) reported encouraging Phase 2 clinical trial data for its investigational therapy, encaleret, presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting. The study focused on post-surgical hypoparathyroidism, a condition challenging to manage due to the need for careful blood and urine calcium balance.
The trial involved ten participants who received encaleret (162 mg twice daily) for up to five days. Researchers observed a significant improvement in calcium management.
A leading endocrinologist noted the difficulty in balancing blood and urine calcium levels with standard treatments, often leading to either low blood calcium or high urinary calcium, both with potentially negative consequences. This expert highlighted the significant unmet need for improved treatment options and expressed enthusiasm over the promising results from this study.
Encaleret demonstrated a rapid and sustained reduction in urinary calcium excretion in most participants. Importantly, 80% of participants achieved normal blood and urine calcium levels within five days of starting encaleret, a stark contrast to the zero percent success rate observed with conventional therapy.
BridgeBio‘s chief medical officer at its affiliate, Calcilytix, explained that the positive results suggest encaleret effectively normalizes calcium levels without stimulating parathyroid hormone (PTH) secretion, likely due to its effect on renal calcium-sensing receptors. Based on this, the company plans to launch a registration clinical study of encaleret for chronic hypoparathyroidism in 2026.
In addition to the encaleret data, BridgeBio also presented preclinical findings for infigratinib, showcasing its potential in treating skeletal disorders. These preclinical results demonstrated positive effects on bone growth in a mouse model of hypochondroplasia and skull development in a Crouzon/Pfeiffer syndrome model. One of these studies has been published in the Journal of Bone and Mineral Research.
BridgeBio is a biopharmaceutical company focused on developing treatments for genetic diseases. The company’s pipeline includes various programs, ranging from early research to advanced clinical trials.
Related
